BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamada R, Hiramatsu N, Oze T, Urabe A, Tahata Y, Morishita N, Kodama T, Hikita H, Sakamori R, Yakushijin T, Yamada A, Hagiwara H, Mita E, Oshita M, Itoh T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Inoue A, Imai Y, Tatsumi T, Hamasaki T, Hayashi N, Takehara T. Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response. Hepatol Res. 2019;49:570-578. [PMID: 30623521 DOI: 10.1111/hepr.13310] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Khoo T, Lam D, Olynyk JK. Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease. World J Gastroenterol 2021; 27(29): 4831-4845 [PMID: 34447229 DOI: 10.3748/wjg.v27.i29.4831] [Reference Citation Analysis]
2 Ohfuji S, Matsuura T, Tamori A, Kubo S, Sasaki S, Kondo K, Ito K, Fukushima W. Lifestyles Associated with Prognosis After Eradication of Hepatitis C Virus: A Prospective Cohort Study in Japan. Dig Dis Sci 2021;66:2118-28. [PMID: 32720018 DOI: 10.1007/s10620-020-06475-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Ma L, Liu J, Wang W, Yang F, Li P, Cai S, Zhou X, Chen X, Zhuang X, Zhang H, Cao G. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients. Future Oncol. 2020;16:675-686. [PMID: 32223423 DOI: 10.2217/fon-2019-0845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shigefuku R, Iwasa M, Katayama K, Eguchi A, Kawaguchi T, Shiraishi K, Ito T, Suzuki K, Koreeda C, Ohtake T, Tokumoto Y, Endo R, Kawamura N, Shiraki M, Habu D, Sakai H, Kato A, Nishiguchi S, Moriwaki H, Suzuki K, Takei Y. Hypozincemia is associated with human hepatocarcinogenesis in hepatitis C virus‐related liver cirrhosis. Hepatol Res 2019;49:1127-35. [DOI: 10.1111/hepr.13388] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
5 Braz AMM, Winckler FC, Binelli LS, Chimeno LG, Lopes LBM, Lima RS, Simões RP, Grotto RMT, Golim MA, Silva GF. Inflammation response and liver stiffness: predictive model of regression of hepatic stiffness after sustained virological response in cirrhotics patients with chronic hepatitis C. Clin Exp Med 2021. [PMID: 33835323 DOI: 10.1007/s10238-021-00708-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Tada T, Nakamura S, Yasuda S, Toyoda H, Loomba R, Izumi N. Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. Hepatol Commun 2021. [PMID: 34676692 DOI: 10.1002/hep4.1833] [Reference Citation Analysis]
7 Osawa L, Tamaki N, Kurosaki M, Kirino S, Watakabe K, Wang W, Okada M, Shimizu T, Higuchi M, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. Int J Mol Sci 2020;21:E3640. [PMID: 32455631 DOI: 10.3390/ijms21103640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kuwano A, Yada M, Nagasawa S, Tanaka K, Morita Y, Masumoto A, Motomura K. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment. J Viral Hepat 2021. [PMID: 34661320 DOI: 10.1111/jvh.13625] [Reference Citation Analysis]
9 Tada T, Kurosaki M, Tamaki N, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Nakamura S, Izumi N. A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response. JGH Open 2022;6:20-8. [PMID: 35071784 DOI: 10.1002/jgh3.12690] [Reference Citation Analysis]
10 Brozzetti S, Tancredi M, Bini S, De Lucia C, Antimi J, D'Alterio C, De Sanctis GM, Furlan C, Malpassuti VC, Lucatelli P, Di Martino M, Bezzi M, Ciardi A, Pascale RM. HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly. Cancers (Basel) 2021;13:3025. [PMID: 34204186 DOI: 10.3390/cancers13123025] [Reference Citation Analysis]
11 Tada T, Nishimura T, Matono T, Yoshida M, Yuri M, Fujiwara A, Yuri Y, Takashima T, Aizawa N, Ikeda N, Enomoto H, Kumada T, Iijima H. Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Hepatol Res 2021;51:860-9. [PMID: 34046970 DOI: 10.1111/hepr.13677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Hagiwara H, Ito Y, Ohta T, Nozaki Y, Iwamoto T, Hosui A, Hiramatsu N, Tahata Y, Sakamori R, Hikita H, Hayashi N. Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C who achieved a sustained virological response through direct‐acting antiviral agents among the working population in Japan. JGH Open. [DOI: 10.1002/jgh3.12745] [Reference Citation Analysis]
13 Nagaoki Y, Imamura M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Hayes CN, Chayama K, Aikata H. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. Hepatol Res 2020;50:1222-33. [PMID: 32767446 DOI: 10.1111/hepr.13554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Muzica CM, Stanciu C, Huiban L, Singeap AM, Sfarti C, Zenovia S, Cojocariu C, Trifan A. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end. World J Gastroenterol 2020; 26(43): 6770-6781 [PMID: 33268960 DOI: 10.3748/wjg.v26.i43.6770] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
15 Abdel-Hamid NM, Abd Allah SG, Hassan MK, Ahmed AAM, Anber NH, Adel Faried I. Possible Protective Potency of Argun Nut (Medemia argun - An Ancient Egyptian Palm) against Hepatocellular Carcinoma in Rats. Nutr Cancer 2021;:1-12. [PMID: 33570439 DOI: 10.1080/01635581.2021.1883683] [Reference Citation Analysis]
16 Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Oshita M, Ohkawa K, Hijioka T, Fukui H, Ito T, Doi Y, Yamada Y, Yakushijin T, Yoshida Y, Tatsumi T, Takehara T; Osaka Liver Forum. Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals. Aliment Pharmacol Ther 2021;54:1340-9. [PMID: 34618934 DOI: 10.1111/apt.16632] [Reference Citation Analysis]
17 Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48:7-17. [PMID: 31347138 DOI: 10.1007/s15010-019-01345-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 11.7] [Reference Citation Analysis]
18 Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Loomba R, Izumi N. Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. Clin Infect Dis 2021:ciaa1307. [PMID: 33544129 DOI: 10.1093/cid/ciaa1307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Asahina Y; Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis. Hepatol Res 2020;50:775-90. [DOI: 10.1111/hepr.13501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
20 Hosui A, Tanimoto T, Okahara T, Ashida M, Ohnishi K, Wakahara Y, Kusumoto Y, Yamaguchi T, Sueyoshi Y, Hirao M, Yamada T, Hiramatsu N. Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA. Hepatol Commun 2021;5:2001-8. [PMID: 34752016 DOI: 10.1002/hep4.1782] [Reference Citation Analysis]
21 Ribaldone DG, Sacco M, Saracco GM. The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. J Clin Med. 2020;9. [PMID: 32092892 DOI: 10.3390/jcm9020563] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Hsu SJ, Yang SS, Kao JH. Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction? J Formos Med Assoc 2020;119:3-11. [PMID: 31627984 DOI: 10.1016/j.jfma.2019.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]